Glioblastoma: Clinical, radiological and biological prognostic factors;Glioblastomes: Facteurs pronostiques cliniques, radiologiques et biologiques

Neurochirurgie

Volumn 56, Issue 6, 2010, Pages 467-476

  Fontaine, D ^a   Paquis, P ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Epidermal growth factor receptor; Gene expression profiling; Glioblastoma; MGMT; p53; Prognosis

Indexed keywords

AGE; AGE DISTRIBUTION; ANALYTIC METHOD; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; COGNITION; DNA METHYLATION; EGFR GENE; FRONTAL CORTEX; GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENETIC CORRELATION; GLIOBLASTOMA; HISTOLOGY; HUMAN; IDH1 GENE; MGMT GENE; NEUROLOGIC DISEASE; PROMOTER REGION; PTEN GENE; RECURSIVE PARTITIONING ANALYSIS; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL TIME; TP53 GENE; TUMOR LOCALIZATION; ARTICLE; BRAIN TUMOR; GENETICS; PROGNOSIS; RADIOGRAPHY;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; PROGNOSIS;

EID: 79953302020     PISSN: 00283770     EISSN: 17730619     Source Type: Journal    
DOI: 10.1016/j.neuchi.2010.07.008     Document Type: Review

References (134)

1. Ammirati M., Vick N., Liao Y. Effect of the extent of surgical resection on survival and quality of life of patients with supratentorial glioblastomas and anaplstic astrocytomas. Neurosurgery 1987, 21:201-206.
2. 6-methyl guanine-DNA methyl transferase, glutathione-S-transferase in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol. Res. 2003, 25:241-248.
3. 6-methyl guanine-DNA methyl transferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma muultiforme. Clin. Cancer Res. 2003, 9:1461-1468.
4. Barker F., Davis D., Chang S., Prados M. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996, 77:1161-1166.
5. Barker F., Prados M., Chang S., Davis D., Gutin P., Lamborn K., Larson D., McDermott M., Sneed P., Wilson C. Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age and survival. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34:803-808.
6. Barker F.G., Simmons M.L., Chang S.M., Prados M.D., Larson D.A., Sneed P.K., Wara W.M., Berger M.S., Chen P., Israel M.A., Aldape K.D. EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:410-418.
7. Batchelor T., Betensky R., Esposito J., Pham L., Dorfman M., Piscatelli N., Jhung S., Rhee D., Louis D. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Cancer Res. 2004, 10:228-233.
8. Baxendine-Jones J., Campbell I., Ellison D. p53 status has no prognosis significance in glioblastomas. Clin. Neuropathol. 1997, 16:332-336.
9. Belanich M., Pastor M., Randall T., Guerra D., Kibitel J., Alas L. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996, 56:783-788.
10. Blan J., Wâger M., Guilhot J., Kusy S., Bataille B., Chantereau T., Lapierre F., Larsen C., Tapon L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J. Neurooncol. 2004, 68:275-283.
11. Bocangel D., Finkelstein S., Schold S., Bhakat K., Mitra S., Kokkinakis D. Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res. 2002, 8:2725-2734.
12. Bouvier-Labit C., Chinot O., Ochi C., Gambarelli D., Dufour H., Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol. Appl. Neurobiol. 1998, 24:381-388.
13. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res. 2003, 59:3059-3063.
14. Brat D., Seiferheld W., Perry A., Hammond R., Murray K., Schulsinger A., Mehta M., Curran W., Group R.T.O. Analysis of 1p, 19q, 9p, and 10q as pronostic markers for high-grade astrocytomas using FISH on tissue microarrays from RTOG trials. Neuro-oncology 2004, 6:96-103.
15. Burger P., Green S. Patients age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 1987, 59:1617-1625.
16. Burger P., Rawlings C., Cox E., McLendon R., Schold C., Bullard D. Clinicopathological correlations in oligodendrogliomas. Cancer 1987, 59:1345-1352.
17. Capper D., Zentgraf H., Balss J., Hartmann C.J., von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009, 118:599-601.
18. Chakravarti A., Seiferheld W., Tu X., Wang H., Zhang H., Ang K., Hammond E., Curran W.J., Mehta M. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:318-327.
19. Crinière E., Kaloshi G., Laigle-Donadey F., Lejeune J., Auger N., Benouaich-Amiel A., Everhard S., Mokhtari K., Polivka M., Delattre J., Hoang-Xuan K., Thillet J., Sanson M. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J. Neurooncol. 2007, 83:173-179.
20. Curran W., Scott C., Horton J., Nelson J., Weinstein A., Fishbach A., Chang C., Rotman M., Asbell S., Krish R. Recursive partitioning analysis of prognostic factors in three RTOG malignant gliomas trials. J. Natl. Cancer Instit. 1993, 85:704-710.
21. Daido S., Takao S., Tamiya T., Ono Y., Terada K., Ito S., Ouchida M., Date I., Ohmoto T., Shimizu K. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions. Oncol. Rep. 2004, 12:789-795.
22. Devaux B., O'Fallon J.R., Kelly P.J. Resection, biopsy and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy and outcome. J. Neurosurg. 1993, 78:767-775.
23. Duerr E., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D.N. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16:2259-2264.
24. Esteller M., Hamilton S., Burger P., Baylin S., Herman J. Inactivation of the DNA repair gene O6-methyl guanine-DNA methyl transferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
25. Esteller M., Garcia-Foncillas J., Andion E., Goodman S., Hidalgo O., Vanaclocha V., Baylin S., Herman J. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350-1354.
26. Esteller M., Herman J. Generating mutations but providing chemosensitivity: the role of O6-methyl guanine-DNA methyl transferase in human cancer. Oncogene 2004, 23:1-8.
27. étienne M.C., Formento J.L., Lebrun-Frenay C., Gioanni J., Chatel M., Paquis P., Bernard C., Courdi A., Bensadoun R.J., Pignol J.P., Francoual M., Grellier P., Frenay M., Milano G. Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome. Clin. Cancer Res. 1998, 4:2383-2390.
28. Fontaine D., Vandenbos F., Lebrun C., Paquis P., Frenay M. Valeurs diagnostique et pronostique des délétions 1p et 19q dans les gliomes de l'adulte. Revue critique de la littérature et implications en pratique clinique. Rev. Neurol. 2008, 164:595-604.
29. Freeman D., Wu L.J.L. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999, 55:96-107.
30. Freije W., Castro-Vargas E., Fang Z., Horvath S., Cloughesy T., Liau L., Mischel P., Nelson S. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004, 64:6503-6510.
31. Fulci G., Ishii N., van Meir E. P53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. 1998, 8:599-613.
32. Fuller C., Wang H., Zhang W., Fuller G., Perry A. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays. J. Neuropathol. Exp. Neurol. 2002, 61:1078-1086.
33. Fuller G., Hess K., Rhee C., Yung W., Sawaya R., Bruner J.W.Z. Molecular classification of human diffuse gliomas by multidimension scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival and reveals clinically-relevant glioma subsets. Brain Pathol. 2002, 12:108-116.
34. Galanis E., Buckner J., Kimmel D., Jenkins R., Alderete B., O'Fallon J., Wang C.H., Scheithauer B.W., James C.D. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol. 1998, 13:717-724.
35. Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Debaillets I., Nozaki M., Diserens A., Hamou M., Dietrich P., Regli L., Janzer R., Bucher P., Stupp R., Tribolet N., Domani d., Hegi E.M. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003, 63:6613-6625.
36. Grunnet M.L., O'Neill A., Gilbert M., Hellman R. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy. Clin. Neuropathol. 2000, 19:230-234.
37. Haas-Kogan D.A., Kogan S.S., Yount G., Hsu J., Haas M., Deen D.F., Israel M.A. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int. J. Radiat. Oncol. Biol. Phys. 1999, 43:399-403.
38. Han S., Yang I., Ahn B., Otero J., Tihan T., McDermott M., Berger M.S., Prados M.D., Parsa A. Clinical characteristics and outcome for a modern series of primary gliosarcoma patients. Cancer 2010, 116:1358-1366.
39. Han S., Yang I., Tihan T., Prados M.D., Parsa A. Primary gliosarcoma: key clinical and pathological distinctions from glioblastoma with implications as a unique oncologic entity. J. Neurooncol. 2010, 96:313-320.
40. He J., Mokhtari K., Sanson M., Marie Y., Kujas M., Huguet S., Leuraud P., Capelle L., Delattre J., Poirier J. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol. 2001, 60:863-871.
41. 6-methyl guanine-DNA methyl transferase promotermethyllation in glioblastoma patients treated with temozolomide. Clin. Cancer. Res. 2004, 10:1871-1874.
42. Hegi M., Diserens A., Gorlia T., Hamou M., de Tribolet N. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
43. Heimberger A., Hlatky R., Suki D., Yang D., Weinberg J., Gilbert M., Sawaya R., Aldape K. Prognostic effect of EGFR and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 2005, 11:1462-1466.
44. Hirai T., Murakami R., Nakamura H., Kitajima M., Fukuoka H., Sasao A., Akter M., Hayashida Y., Toya R., Oya N., Awai K., Iyama K., Kuratsu J., Yamashita Y. Prognostic value of perfusion mr imaging of high-grade astrocytomas: long-term follow-up study. Am. J. Neuroradiol. 2008, 29:1505-1510.
45. Homma T., Fukushima T., Vaccarella S., Yonekawa Y., Di Patre P., Franceschi S., Ohgaki H. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol. 2006, 65:846-854.
46. Houillier C., Lejeune J., Benouaich-Amiel A., Laigle-Donadey F., Criniere E., Mokhtari K., Thillet J., Delattre J., Hoang-Xuan K., Sanson M. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006, 106:2218-2223.
47. Huang H., Colella S., Kurrer M., Yonekawa Y., Kleihues P., Ohgaki H. Gene expression profiling of low-grade diffuse astyrocytomas by cDNA arrays. Cancer Res. 2000, 60:6868-6874.
48. Huncharek M., Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res. 2000, 12:107-112.
49. Ichimura K., Pearson A., Kocialkowski S., Backlund L., Chan R., Jones D., Collins V. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009, 11:341-347.
50. Iwadate Y., Fujimoto M., Tagawa M., Namba H., Sueyoshi K., Hirose T., Sakiyama S. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int. J. Cancer 1996, 69:236-240.
51. Jaros E., Perry R., Adam P., Kelly P., Crawford P., Kalbag R., Mendelow A., Sengupta R., Pearson A. Prognostic implications of p53 protein EGFR and Ki-67 labelling in brain tumors. Br. J. Cancer 1992, 66.
52. Kamiryo T., Tada K., Shiraishi T., Shinojima N., Kochi M., Ushio Y. Correlation between promoter hypermethylation of the O6-methyl guanine-DNA methyl transferase gene and prognosis in patients with high grade astrocytic tumors treated with surgery, radiotherapy, and ACNU-based chemotherapy. Neurosurgery 2004, 54:349-357.
53. Kang S., Kim J., Nam D., Park K. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol. Med. Chir. 2005, 45:232-239.
54. 6-methylguanine DNA methyltransferasestatus determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J. Neurooncol. 2010, 17. (Epub ahead of print). 10.1007/s11060-010-0267-9.
55. Karkavelas G., Mavropolou S., Fountzilas G., Christoforidou V., Karavelis A., Foroglou G., Papadimitriou C. Correlation of PCNA assessment, histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res. 1995, 15:531-536.
56. Karnofsky D., Abelman W., Craver L., Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948, 1:634-656.
57. Kato Y., Jin G., Kuan C., McLendon R., Bigner D. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 2009, 390:547-551.
58. Kim S., Dougherty E., Shmulevich I., Hess K., Hamilton S., Trent J., Fuller G., Zhang W. Identification of combination gene sets for glioma classification. Mol. Cancer Ther. 2002, 1:1229-1236.
59. Kimmelman A., Ross D., Liang B. Loss of heterozygoty on chromosome 10p in human gliomas. Genomics 1996, 34:250-254.
60. Kirla R., Salminen E., Huhtala S., Nuutinen J., Talve L., Haapasalo H., Kalim H. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy. J. Neurooncol. 2000, 46:71-80.
61. Kleihues, P., Cavenee, W., 2000. Pathology and genetics of tumours of the nervous system.
62. Korkolopoulou P., Christodoulou P., Kapralos P., Exarchakos M., Bisbiroula A., Hadjiyannakis M., Georgountzos C., Thomas-Tsagli E. The role of p53 MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract. 1997, 193:767-775.
63. Korshunov A., Sycheva R., Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients âge<50 years. Cancer 2005, 104:825-832.
64. Kozak K., Mahadevan A., Moody J. Adult gliosarcoma: epidemiology, natural history and factors associated with outcome. Neuro-oncology 2008, 11:183-191.
65. Kraus J., Koopmann J., Kaskel P., Maintz D., Brandner S., Schramm J., Louis D., Wiestler O., von Deimling A. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 1995, 54:91-95.
66. Kraus J., Lamszus K., Glesmann N., Beck M., Wolter M., Sabel M., Krex D., Klockgether T., Reifenberger G., Schlegel U. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta. Neuropathol. 2001, 101:311-320.
67. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J., Heese O., Reifenberger G., Weller M., Schackert G. Long term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606. German Glioma Network.
68. Kumar P., Singh S., Kumar P., Krishnani N., Datta N. Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. J. Cancer Res. Ther. 2008, 4:164-168.
69. Kyritsis A., Bondy M., Hess K., Cunningham J., Zhu D., Amos C., Yung W., Levin V., Bruner J. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res. 1995, 1:1617-1622.
70. Lacroix M., Abi-Said D., Fourney D., Gokaslan Z., Shi W., DeMonte F., Lang F., McCutcheon M.S.J., Holland H., Hess E., Michael K., Miller C., Sawaya D.R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival. J. Neurosurg. 2001, 95:190-198.
71. Lamborn K., Chang S., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncology 2004, 6:227-235.
72. Laws E., Parney I., Huang W., Anderson F., Morris A., Asher A., Lillehei K., Bernstein M., Brem H., Sloan A., Berger M., Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant gliomas: data from the Glioma Outcomes Project. J. Neurosurg. 2003, 99:467-473. Investigators atGO.
73. Leon S., Folkerth R., Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996, 77:362-372.
74. Levine A. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
75. Li X., Jin H., Lu Y., Oh J., Chang S., Nelson S. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed. 2004, 17:10-20.
76. Ljubimova J., Khazenzon N., Chen Z., Neyman Y., Turner L., Riedinger M. Gene expression abnormalities in human glial tumors identified by array. Int. J. Oncol. 2001, 18:287-295.
77. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W., 2007. WHO classification of the tumors of the central nervous system.
78. Margetts J., Kalyan-Raman U. Giant-celled glioblastoma of brain: a clinicoradiological study of 10 cases. Cancer 1989, 63:524-531.
79. Matsumoto R. Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme. Hokkaido Igaku. Zashi. 1998, 73:407-417.
80. Meyers C., Hess K., Yung W., Levin V. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J. Clin. Oncol. 2000, 18:646-650.
81. Mineo J., Bordron A., Baroncini M., Ramirez C., Maurâge C., Blond S., Dam-Hieu P. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta. Neurochir. (Wien) 2007, 149:245-252.
82. Mirimanoff R., Gorlia T., Mason W., van den Bent M., Kortmann R., Fisher B., Reni M., Brandes A., Curschmann J., Villa S., Cairncross J., Allgeier A., Lacombe D., Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive Partinioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. 2006, 24:2563-2569.
83. Mischel P., Cloughesi T., Nelson S. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat. Neurosci. Rev. 2004, 5:782-792.
84. Newcomb E., Cohen H., Lee S., Bhalla S., Bloom J., Hayes R., Miller D. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998, 8:655-667.
85. Nitta T., Sato K. Prognostic implications of the extent of resection in patients with intracranial malignant gliomas. Cancer 1995, 75:2727-2731.
86. Nobusawa S., Watanabe K., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predicitive factor of secondary glioblastomas. Clin. Cancer Res. 2009, 15:6002-6007.
87. 6-methyl guanine-DNA methyl transferase activity, p53 gene statusand BCNU resistance in mouse astrocytes. Carcinogenesis 1999, 20:2361-2365.
88. Nutt C., Mani D., Betenski R., Tamayo P., Cairncross J., Ladd C., Pohl U., Hartmann C., McLaughlin M., Batchelor T., Black P., vonDeimling A., Pomeroy S., Golub T., Louis D. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003, 63:1602-1607.
89. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005, 25:1-7.
90. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005, 64:479-489.
91. Olson J., Barnett D., Yang J., Assieti R., Cotsonis G., James C. Gene amplification as a prognostic factor in primary brain tumors. Clin. Cancer Res. 1998, 4:215-222.
92. Pallud J., Mandonnet E., Kujas M., Guillevin R., Galanaud D., Taillandier L., Duffau H., Capelle L. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann. Neurol. 2006, 60:380-383.
93. Parsons D., Jones S., Zhang X., Cheng-Ho Lin J., Leary R., Angenendt P., Mankoo P., Carter H., Siu I., Gallia G., Olivi A., McLendon R., Rasheed A., Keir S., Nikolskaya T., Nikolsky Y., Busam D., Tekleab H., Diaz L., Hartigan J., Smith D., Strausberg R., Marie S., Shinjo S., Yan H., Riggins G., Bigner D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V., Kinzler K. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807.
94. Paz M., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., Garcia-Lopez J., Piquer J., Safont M., Balana C., Sanchez-Cespedes M., Carcia-Villanueva M., Arribas L., Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004, 10:4933-4938.
95. Pope W., Sayre J., Perlina A., Villablanca J., Mischel P., Cloughesy T. MR imaging correlates of survival in patients with high-grade gliomas. Am. J. Neuroradiol. 2005, 26:2466-2474.
96. Quan A., Barnett G., Lee S., Vogelbaum M., Toms S., Staugaitis S., Prayson R., Peereboom D., Stevens G., Cohen B., Suh J. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:695-703.
97. Rasheed B., Fuller G., Friedman A., Bigner S. Loss of heterozygoty for 10q loci in human gliomas. Genes Chromosomes Cancer 1992, 5:75-82.
98. Rasheed B., Herndon J., Stenzel T., Raetz J., Kendelhardt J., Friedman H., Friedman A., Bigner D., Bigner S., McLendon R. Molecular markers of prognosis in astrocytic tumors. Cancer 2002, 94:2688-2697.
99. Rickman D., Bobek M., Misek D., Kuick R., Blaivas M., Kurnit D., Taylor J., Hanash S. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001, 61:6885-6891.
100. Sallinen S., Sallinen P., Haapasaio H., Helin H., Helen P., Schraml P., Kallioniemi O., Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarrays and tissue chip techniques. Cancer Res. 2000, 60:6617-6622.
101. Sano T., Lin H., Chen X. Differential expression of MMAC/PTEN gene in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999, 59:1820-1824.
102. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009, 27:4150-4154.
103. Schmidt M., Antweiler S., Urban N., Mueller W., Kuklik A., Meyer-Puttlitz B., Wiestler O., Louis D., Fimmers R., von Deimling A. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol. 2002, 61:321-328.
104. Schoenegger K., Oberndorfer S., Wuschitz B., Struhal W., Hainfellner J., Prayer D., Heinzl H., Lahrmann H., Marosi C., Grisold W. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?. Eur. J. Neurol. 2009, 16:874-878.
105. Shai R., Shi T., Kremen T., Horvath S., Liau L., Cloughesi T., Mischel P., Nelson S. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003, 22:4918-4923.
106. Shaw E., Seiferheld W., Scott C., Coughlin C., Leibel S., Curran D., Mehta M. Reexamining the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) for glioblastome multiforme (GBM) patients. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57:S135-S136.
107. Shih H., Betensky R., Dorfman M., Louis D., Loeffler J., Batchelor T. Genetic analyses for predictors of radiation response in glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:704-710.
108. Shinojima N., Tada K., Shiraishi S., Kamiryo T., Kochi M., Nakamura H., Makino K., Saya H., Hirano H., Kuratsu J., Oka K., Ishimaru Y., Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63:6962-6970.
109. Shinojima N., Kochi M., Hamada J., Nakamura H., Yano S., Makino K., Tsuiki H., Tada K., Kuratsu J., Ishimaru Y., Ushio Y. The influence of sex and the presence of giant cells on postoperative long term survival in adult patients with supratentorial glioblastoma multiforme. J. Neurosurg. 2004, 101:219-226.
110. 6-methyl guanine-DNA methyl transferase - deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 1999, 5:807-814.
111. Simmons M., Lamborn K., Takahashi M., Chen P., Israel M., Berger M., Godfrey T., Nigro J., Prados M., Chang S., Barker F., Adalpe K. Analysis of complex relationships between âge, p53, EGFR and survival in glioblastoma patients. Cancer Res. 2001, 61:1122-1128.
112. Simpson J., Horton J., Scott C., Curran W., Rubin P., Fischbach J., Isaacson S., Rotman M., Asbell S., Nelson J., Weinstein A., Nelson D. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive radiation therapy oncology group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 1993, 26:239-244.
113. Smith J., Jenkins R. Genetic alterations in adult diffuse glioma: occurence, significance and prognostic implications. Front. Biosci. 2000, 5:d213-231.
114. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., O'Fallon J.R., Schaefer P.L., Scheithauer B.W., James C.D., Buckner J.C., Jenkins R.B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
115. Sonoda Y., Kumabe T., Watanabe M., Nakazato Y., Kanamori M., Tominaga T. Long term survivors of glioblastoma: clinical features and molecular analysis. Acta. Neurochir. (Wien) 2009, 151:1349-1358.
116. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:392-401. Group AGS.
117. Stupp R., Mason W., van den Bent M., Weller M., Fisher B., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
118. Tada K., Matsumoto K., Iggo R., Onimaru R., Shirato H., Sawamura Y., Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998, 58:1793-1797.
119. Taphoorn M., Klein M. Cognitive deficit in adult patients with brain tumours. Lancet. Neurol. 2004, 3:159-168.
120. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. The Cancer Genome Atlas (TCGA) Research Network.
121. Tohma Y., Gratas C., Biernat W., Peraud A., KFukuda M., Yonekawa Y. PTEN mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 1998, 57:684-689.
122. Torp S.H., Helseth E., Dalen A., Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta. Neurochir. (Wien) 1992, 117:182-186.
123. Tucha O., Smely C., Preier M., Lange K. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 2000, 47:324-333.
124. Ueki K., Nishikawa R., Nakazato Y., Hirose T., Hirato J., Funada N., Fujimaki T., Hojo S., Kubo O., Ide T., Usui M., Ochiai C., Ito S., Takahashi H., Mukasa A., Asai A., Kirino T. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin. Cancer Res. 2002, 8:196-201.
125. Verhaak R., Hoadley K., Purdom E., Wang V., Qi Y., Wilkerson M., Miller R., Ding L., Golub T., Mesirov J., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H., Hodgson G., James D., Sarkaria J., Brennan C., Kahn A., Spellman P., Wilson R., Speed T., Gray J., Meyerson M., Getz G., Perou C., Hayes D. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17:98-110. The Cancer Genome Atlas Research Network.
126. von Deimling A., Louis D.N., von Ammon K., Petersen I., Hoell T., Chung R.Y., Martuza R.L., Schoenfeld D.A., Yasargil M.G., Wiestler O.D., et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. 1992, 77:295-301.
127. Wakimoto H., Aoyagi M., Nakayama T., Nagashima T., Shinji Y., Masashi T., Kimiyoshi H. Prognostic significance of Ki67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996, 77:373-380.
128. Wager M., Menei P., Guilhot J., Levillain P., Michalak S., Bataille B., Blanc J.L., Lapierre F., Riogard P., Milin S., Duthe F., Bonneau D., Larsen C.J., Karayan-Tapon L. Prognostic molecular markers with no impact on decision-maling: the paradox of gliomas based on a prospective study. Br. J. Cancer. 2008, 98:1830-1838.
129. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain. Pathol. 1996, 6:217-223. (discussion 223-214).
130. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J., Schramm J., Westphal M., Schackert G., Simon M., Tonn J., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O.D., Reifenberger G., von Deimling A., Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J. Clin. Oncol. 2009, 27:5743-5750.
131. Yan H., Parsons D., Jin G., McLendon R., Rasheed A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K., Velculescu V., Vogelstein B., Bigner D. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
132. Zhou Y., Tan F., Hess K., Yung W. The expression of PAX6, PTEN, VEGF, and EGFR in gliomas: relationship to tumor grade and survival. Clin. Cancer Res. 2003, 9:3369-3375.
133. Zhu A., Shaeffer J., Leslie S., Kolm P., El-Mahdi A.M. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34:809-815.
134. Zlatescu M., Tehrani Yazdi A., Sasaki H., Megyesi J., Betensky R., Louis D., Cairncross J. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001, 61:6713-6715.